Literature DB >> 27317832

Structural insights into the multi-determinant aggregation of TDP-43 in motor neuron-like cells.

F Bozzo1, I Salvatori2, F Iacovelli3, A Mirra1, S Rossi4, M Cozzolino5, M Falconi3, C Valle6, M T Carrì7.   

Abstract

TDP-43 is aggregated in patients with ALS and FLTD through mechanisms still incompletely understood. Since aggregation in the cytosol is most probably responsible for the delocalization and loss of proper RNA-binding function of TDP-43 in the nucleus, interception of the formation of aggregates may represent a useful therapeutic option. In this study, we investigated the relative importance of the N-terminal and C-terminal moieties of TDP-43 in the aggregation process and the weight of each of the six cysteine residues in determining unfolding and aggregation of the different domains. We report that cytoplasmic inclusions formed by WT and mutant TDP-43 in motor neuron-like NSC34 cells are redox-sensitive only in part, and contain at least two components, i.e. oligomers and large aggregates, that are made of different molecular species. The two N-terminal cysteine residues contribute to the seeding for the first step in oligomerization, which is then accomplished by mechanisms depending on the four cysteines in the RNA-recognition motifs. Cysteine-independent large aggregates contain unfolded isoforms of the protein, held together by unspecific hydrophobic interactions. Interestingly, truncated isoforms are entrapped exclusively in oligomers. Ab initio modeling of TDP-43 structure, molecular dynamics and molecular docking analysis indicate a differential accessibility of cysteine residues that contributes to aggregation propensity. We propose a model of TDP-43 aggregation involving cysteine-dependent and cysteine-independent stages that may constitute a starting point to devise strategies counteracting the formation of inclusions in TDP-43 proteinopathies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALS; Amyotrophic lateral sclerosis; Cysteine; Large aggregates; N-terminal domain; Neurodegeneration; Oligomers; Protein aggregation; TDP-43

Mesh:

Substances:

Year:  2016        PMID: 27317832     DOI: 10.1016/j.nbd.2016.06.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  15 in total

1.  Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS.

Authors:  Kaitlin Weskamp; Elizabeth M Tank; Roberto Miguez; Jonathon P McBride; Nicolás B Gómez; Matthew White; Ziqiang Lin; Carmen Moreno Gonzalez; Andrea Serio; Jemeen Sreedharan; Sami J Barmada
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 2.  Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.

Authors:  Alistair Wood; Yuval Gurfinkel; Nicole Polain; Wesley Lamont; Sarah Lyn Rea
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 3.  Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications.

Authors:  Niccolò Candelise; Silvia Scaricamazza; Illari Salvatori; Alberto Ferri; Cristiana Valle; Valeria Manganelli; Tina Garofalo; Maurizio Sorice; Roberta Misasi
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

Review 4.  Cysteine Modifications in the Pathogenesis of ALS.

Authors:  Cristiana Valle; Maria Teresa Carrì
Journal:  Front Mol Neurosci       Date:  2017-01-23       Impact factor: 5.639

5.  The N-terminal dimerization is required for TDP-43 splicing activity.

Authors:  Lei-Lei Jiang; Wei Xue; Jun-Ye Hong; Jun-Ting Zhang; Min-Jun Li; Shao-Ning Yu; Jian-Hua He; Hong-Yu Hu
Journal:  Sci Rep       Date:  2017-07-21       Impact factor: 4.379

6.  Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation.

Authors:  Tariq Afroz; Eva-Maria Hock; Patrick Ernst; Chiara Foglieni; Melanie Jambeau; Larissa A B Gilhespy; Florent Laferriere; Zuzanna Maniecka; Andreas Plückthun; Peer Mittl; Paolo Paganetti; Frédéric H T Allain; Magdalini Polymenidou
Journal:  Nat Commun       Date:  2017-06-29       Impact factor: 14.919

7.  Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum.

Authors:  Hamideh Shahheydari; Audrey Ragagnin; Adam K Walker; Reka P Toth; Marta Vidal; Cyril J Jagaraj; Emma R Perri; Anna Konopka; Jessica M Sultana; Julie D Atkin
Journal:  Front Mol Neurosci       Date:  2017-05-10       Impact factor: 5.639

8.  Single cell imaging and quantification of TDP-43 and α-synuclein intercellular propagation.

Authors:  Sivan Peled; Dorin Sade; Yaron Bram; Ziv Porat; Topaz Kreiser; Michael Mimouni; Alexandra Lichtenstein; Daniel Segal; Ehud Gazit
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

Review 9.  Mechanistic Insights of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis: An Update on a Lasting Relationship.

Authors:  Niccolò Candelise; Illari Salvatori; Silvia Scaricamazza; Valentina Nesci; Henri Zenuni; Alberto Ferri; Cristiana Valle
Journal:  Metabolites       Date:  2022-03-09

10.  Platelet phosphorylated TDP-43: an exploratory study for a peripheral surrogate biomarker development for Alzheimer's disease.

Authors:  Rodger Wilhite; Jessica M Sage; Abdurrahman Bouzid; Tyler Primavera; Abdulbaki Agbas
Journal:  Future Sci OA       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.